Research progress on endogenous small-molecule phenolics and the proposal of "phenolomics"
10.16438/j.0513-4870.2023-0728
- VernacularTitle:内源性小分子酚类物质研究进展及“酚组学”的提出
- Author:
Hong-qian KUI
1
;
Chuan-xin LIU
2
;
Qiang WANG
1
;
Hai-feng ZHAI
3
;
Jian-mei HUANG
1
Author Information
1. School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China
2. School of Clinical Medicine, Henan University of Science and Technology, Endocrinology and Metabolism Center, The First Affiliated Hospital of Henan University of Science and Technology, Henan Key Laboratory of Rare Diseases, Luoyang 471003, China
3. National Institute on Drug Dependence, Peking University, Beijing 100191, China
- Publication Type:Research Article
- Keywords:
phenolomics;
endogenous small-molecule phenol;
natural small-molecule phenol;
psychiatric disease;
catecholamine neurotransmitter
- From:
Acta Pharmaceutica Sinica
2024;59(2):336-349
- CountryChina
- Language:Chinese
-
Abstract:
Small-molecule phenolic substances widely exist in animals and plants, and have some shared biological activities. The metabolism of phenylalanine and tyrosine in the human body, and especially the metabolism of catecholamine neurotransmitters, produces endogenous small-molecule phenols. Endogenous small-molecule phenolic substances are functionally related to the important physiological processes and the occurrence of mental diseases in humans and some animals, which are systematically sorts and summarized in this review. Integrating the previous experimental research and literature analysis on natural small-molecule phenols by our research group, the understanding of the hypothesis that "small-molecule phenol are pharmacological signal carriers" was deepened. Based on above, the concept of "phenolomics" was further proposed, analyzed the research direction and research content which can bring into the knowledge framework of phenolomics. The induction of phenolomics will provide wider perspectives on explaining the pharmacological mechanism of drugs, discovering new drug targets, and finding biomarkers of mental diseases.
